Acquired resistance has curtailed cancer survival since the dawn of the chemotherapy age more than half a century ago. Although the application of stem cell (SC) concepts to cancer captured the imagination of scientists for many years, only the last decade has yielded substantial evidence that cancer SCs (CSCs) contribute to chemotherapy resistance. Recent studies suggest that the functional and molecular properties of CSCs constitute therapeutic opportunities to improve the efficacy of chemotherapy. Here we review how these properties have stimulated combination strategies that suppress acquired resistance across a spectrum of malignancies. The clinical implementation of these strategies promises to rejuvenate the effort against an enduring challenge.
INTRODUCTION
Conventional and targeted chemotherapeutics are a standard of care in clinical oncology today. 1 Their widespread application stems in part from the observation that chemotherapy often succeeds in reducing tumor burden and consequently improving survival. However, patients who benefit from chemotherapy in this context commonly progress to a refractory state. This phenomenon is known as acquired (or secondary) resistance and is responsible for the failure of many chemotherapeutic agents.
The phenomenon of acquired resistance implies that many cancers exhibit intratumoral heterogeneity, insofar as some tumor cells survive chemotherapy exposure and contribute to disease progression, whereas others perish. Indeed, intratumoral heterogeneity is now understood to be a defining characteristic of cancer. 2 Several mechanisms of intratumoral heterogeneity are well described, including genetic mutation and interactions with the microenvironment. 2 Notably, substantial evidence suggests that these mechanisms of heterogeneity significantly contribute to the phenomenon of acquired resistance to chemotherapy. For example, genetic mutations in BCR-ABL result in acquired resistance to imatinib in chronic myeloid leukemia (CML). 3 In addition to these well-established mechanisms, the last several years have featured renewed interest in the possible contribution of cancer stem cells (CSCs) to intratumoral heterogeneity and acquired resistance. The CSC model proposes that some malignancies are hierarchically organized with a CSC population that exhibits the properties of tumor-initiating capacity and self-renewal in serial transplantation assays. [4] [5] [6] [7] [8] The CSC model comprises an attractive framework to explain acquired resistance, because chemotherapy-resistant CSCs would be expected to be particularly well suited to initiate progressive disease. Indeed, as early as the 1960s, experimental evidence that hematological malignancies contain small fractions of slowly cycling cells led to speculation that these fractions contain CSCs that survive antiproliferative chemotherapeutics and contribute to disease progression. 4 In recent years, this hypothesis has been considerably revisited with the benefit of new chemotherapeutics as well as improved technologies and experimental models. Here we review the recent and growing body of evidence that supports the contribution of CSCs to chemotherapy resistance across a range of hematological and solid malignancies. We focus on CSC properties that promote chemotherapy resistance, as well as how these properties have stimulated combination strategies that suppress acquired resistance in preclinical models. We also review the evolving complexity of the CSC model and its application to chemotherapy resistance. Finally, we discuss the future opportunities and challenges that this model will introduce to the clinical oncology field.
candidates for consolidation therapies with additional chemotherapy, as well as autologous or allogenic hematopoietic stem cell (SC) transplantation. Unfortunately, recurrence of AML is frequent if patients who experience a complete response following chemotherapy are not subject to hematopoietic SC transplantation, suggesting that residual cells survive chemotherapy exposure and contribute to disease progression.
In a series of studies spanning two decades, Dick et al. established that AML is hierarchically organized containing a CD34 þ CSC population that sustains serial transplantation. 10, 11 More recently, studies have implicated AML SCs in chemotherapy resistance. For example, in a large cohort of AML patient samples, high CSC frequency at diagnosis correlated with high frequency of residual disease after chemotherapy and poor prognosis. 12 In addition, AML minimal residual disease detected during complete remission was enriched in CD34 þ CD38 À cells, and their abundance after therapy was associated with subsequent relapse. 13 In AML patient-derived xenografts, standard therapy with cytarabine markedly reduced peripheral blood leukemic burden, whereas bone marrow AML SCs exhibited more robust chemotherapy resistance than their non-CSC counterparts.
14 Moreover, the surviving cytarabine resistant cells efficiently engrafted into secondary recipients, recapitulating an important CSC criterion.
Similarly, the contribution of CSCs to chemotherapy resistance has been documented in CML. CML was the first neoplasm to be associated with a diagnostic molecular alteration and treated with targeted chemotherapy. 15 CML cells are characterized by a translocation between chromosomes 9 and 22 resulting in the oncogenic BCR-ABL tyrosine kinase. Targeted therapies for the treatment of CML using tyrosine kinase inhibitors (TKIs) that inhibit BCR-ABL activity include imatinib, as well as second-generation inhibitors like dasatinib and nilotinib. While CML patient survival dramatically improved following the clinical implementation of TKIs, patients experience disease recurrence when therapy is discontinued. This observation suggests that TKIs do not completely eradicate CML cells even when disease burden is reduced below detectable levels.
CML has historically been one of the most intensively studied neoplasms, and decades of research support the hypothesis that CML is a CSC malignancy. 16 Soon after the initiation of clinical trials with imatinib, evidence began to emerge that CML SCs survive TKI therapy. In an initial study, culture of peripheral blood cells from CML patients treated with imatinib resulted in the enrichment of quiescent CD34 þ leukemic cells. 17 Further, the presence of BCR-ABL was confirmed in CD34 þ cells from the bone marrows of patients in complete cytogenetic response (CCR) following imatinib treatment. 18 Interestingly, these findings have also been observed in patients experiencing long-term CCR. 19, 20 In addition, the contribution of CSCs to imatinib resistance has been validated in several mouse models of CML. [21] [22] [23] For example, in a xenograft model of blast crisis, CSCs were profoundly enriched in the bone marrow niche following TKI therapy and efficiently engrafted into secondary recipients. 23 In summary, a substantial and growing number of studies using clinical samples as well as in vivo modeling approaches suggest that CSCs in both AML and CML may contribute to resistance to standard chemotherapy. Carcinomas Today, the treatment for most epithelial malignancies (also called carcinomas) is multifaceted, including surgery, radiation and traditional cytotoxic as well as targeted chemotherapeutics. While these therapeutic approaches have improved the survival of many carcinoma patients, advanced disease frequently exhibits acquired resistance to chemotherapy, resulting in progression and fatality. Therefore, the mechanisms underlying acquired resistance in epithelial malignancies are an active area of investigation.
The earlier evidence of hierarchical organization in hematological malignancies was later followed by similar studies in several carcinomas. Al-Hajj et al. 24 first reported that the CD44 þ / CD24 À cell surface phenotype enriched for CSCs in breast cancer. Importantly, Yu et al. 25 demonstrated that clinical specimens treated with chemotherapy exhibited higher frequencies of mammosphere-forming and CD44 þ /CD24 À cells than chemotherapy-naive specimens, and similar results were observed in an independent study by Li et al. 26 Breast CSCs have also been enriched by virtue of their elevated aldehyde dehydrogenase (ALDH) activity, 27 and ALDH1-positive cells in axillary lymph-node metastases after chemotherapy has been associated with disease recurrence. 28 Moreover, a breast CSC transcriptional signature was enriched in clinical samples following therapy with either hormone or chemotherapy. 29 In experimental models, breast CSC frequency increased following treatment with standard chemotherapeutics in both cell line 25 and patient-derived 30 xenografts. Finally, breast cancers that overexpress HER2 are currently treated with targeted therapies including the antibody trastuzumab. 31 Interestingly, while HER2 is a regulator of CSCs in HER2-overexpressing breast cancer, 26, [32] [33] [34] commonly observed PTEN inactivation results in the expansion of a trastuzumab-resistant CSC population. 35 Collectively, these studies suggest that breast CSCs contribute to standard chemotherapy resistance in both patients and experimental models.
Substantial evidence has also emerged that colorectal cancer exhibits hierarchical organization, and colorectal CSCs have been enriched with the CD133 47 In summary, a substantial and growing body of evidence suggests that CSCs may contribute to acquired chemotherapy resistance in several carcinomas that together constitute the large majority of cancer morbidity and mortality in humans.
Glioblastoma multiforme (GBM) GBM is the most common and the most aggressive primary brain malignancy. While its clinical prognosis is considerably less favorable, the therapeutic landscape for GBM is similar to that for carcinomas, including surgery, radiotherapy and chemotherapy. Singh et al. 50 demonstrated that GBM CSCs were enriched by a CD133 þ cell surface phenotype. Interestingly, CD133 þ CSCs from primary GBM cell lines were significantly more resistant to the DNA-damaging agent temozolomide than CD133 -cells. 51 Further, CD133 þ CSC-enriched populations from the hypoxic inner mass of GBM biopsies were more resistant to temozolomide than their CD133
À counterparts from peripheral areas. 52, 53 Finally, in an elegant mouse model of GBM relapse after chemotherapy, temozolomide exposure stimulated rare quiescent Nestin þ cells to proliferate and repopulate tumors with Nestin -cells. 54 Collectively, these studies suggest that GBM CSCs may recapitulate the chemotherapy-resistant property observed in hematological and epithelial malignancies.
TARGETING CSCS IMPROVES THE EFFICACY OF CHEMOTHERAPY
The mounting evidence that CSCs contribute to acquired chemotherapy resistance across a broad range of malignancies has raised an important question: can knowledge extracted from CSC studies stimulate the design of new therapies that improve the efficacy of chemotherapy and accordingly, patient survival? In this context, it is of particular interest that the distinct functional and molecular properties of CSCs may constitute therapeutic vulnerabilities that can be exploited for the development of novel combination strategies (Table 1 ). These CSC properties include self-renewal, lack of differentiation, quiescence, a distinct epigenetic state, deregulation of apoptotic/survival pathways, metabolism and interactions with the microenvironment, among others ( Figure 2 ). In the remainder of this review, we focus on therapeutic strategies that have targeted these CSC properties to improve the efficacy of standard chemotherapy.
Self-renewal CSCs are endowed with the capacity to self-renew, and this property is validated experimentally with an in vivo serial transplantation assay. [5] [6] [7] [8] Alternatively, the sphere assay may provide more limited insights. 5, 6, 8 Recent studies suggest that CSC self-renewal is regulated by several developmental pathways, and these studies have stimulated combination strategies that improve the efficacy of chemotherapy.
For example, the Hedgehog (Hh) signal transduction cascade is a conserved developmental pathway that is implicated in the pathogenesis of many tumor types. 55 Genetic modulation of this pathway potently influenced CML pathogenesis by regulating the self-renewal of CSCs. 56 Notably, inhibition of the Hh pathway with the Smo antagonist cyclopamine both improved the efficacy of TKI therapy by depleting the CSC population and significantly increased the survival of CML-bearing mice. Moreover, the critical role of the Hh pathway in regulating the CML SC pool was confirmed in another study in which genetic and pharmacological inhibition of the Hh pathway improved survival in a mouse model of imatinib resistant disease. 57 Similarly, recent studies suggest that the Wnt/b-catenin pathway also regulates CML SC self-renewal. Indeed, genetic deletion of b-catenin, the effector of canonical Wnt signaling, 58 abrogated the development of CML following bone marrow transplantation into secondary recipients. 59 Moreover, b-catenin deletion also resulted in a profound loss of residual CML SCs in the bone marrows of mice following imatinib therapy. 60 Notably, these observations stimulated a novel combination strategy with the COX inhibitor indomethacin that prolonged survival in a CML transplantation model. The TGFb family is a critical regulator of developing as well as adult tissues, and its deregulation exerts myriad effects on tumorigenesis and tumor progression. 61 In pancreatic cancer, the Nodal-ALK4-SMAD4 axis was reported to regulate the selfrenewal of CD133 þ CSCs. 62 Importantly, when combined with a stroma-targeting Hh inhibitor, the combination of the standard chemotherapeutic gemcitabine with the ALK inhibitor SB431542 potently suppressed the growth of primary human pancreatic cancer xenografts. 62 More recently, the TGFb family was also implicated in the self-renewal of triple-negative breast CSCs, and pharmacological inhibition of the TGFb type I receptor improved the efficacy of the antimitotic agent paclitaxel in in vivo models. 63 Finally, similar to the role of other developmental signaling pathways, Notch regulates both normal breast development and breast cancer progression. 64 Moreover, Notch pathway inhibition reduced the self-renewal of breast CSCs, 65 and antibodies against either Dll4 30 or Notch1 65 improved the efficacy of taxane therapy in patient-derived xenografts. Likewise, in a recent study, inhibition of Notch cleavage by hampering g-secretase activity reduced CSC self-renewal and improved the efficacy of docetaxel in patient-derived breast cancer xenografts. 66 Altogether, these studies suggest that CSC self-renewal promotes tumor recurrence after standard chemotherapy, and that targeting this property may constitute a promising strategy to inhibit disease progression.
Differentiation
Differentiation of malignant cells to less-aggressive phenotypes has long captured the imagination of scientists as a unique modality of anticancer therapy. Could proliferative neoplasia be reduced to an indolent state by agents that promote differentiation? Indeed, one of the greatest of successes in modern oncology has been the high cure rates achieved in acute promyelocytic leukemia with all trans retinoic acid differentiation therapy. 67 Intriguingly, a number of studies have reported that CSCs lack differentiation markers. For example, breast, colon and prostate CSCs lacked cytokeratin epithelial differentiation markers, 25, 37, 47 Suppressing chemotherapy resistance by anti-CSC agents SJ Vidal et al whereas GBM CSCs lacked glial fibrillary acidic protein. 50 These observations suggest differentiation therapy may constitute a strategy to sensitize CSCs to chemotherapy.
In this context, recent studies suggest that TGFb family ligands may induce CSC differentiation. An early study reported that exposure of GBM CSCs to BMP4 potently suppressed their tumorinitiating capacity through a SMAD-dependent differentiation mechanism, 68 and similar results were reported with BMP7. 69, 70 Moreover, CSC-enriched populations from the hypoxic inner mass of GBM biopsies were sensitized to chemotherapy by the differentiating agent BMP2. 53 Finally, exposure of colorectal CSCs to BMP4 resulted in differentiation, loss of tumor-initiating capacity and profoundly improved the efficacy of 5-fluorouracil and oxaliplatin chemotherapy in vivo. 71 These studies suggest that the promise of differentiation therapy may find new applications in targeting chemotherapy-resistant CSCs.
Quiescence Quiescence is the maintenance of a non-dividing state while retaining the capacity to reenter the proliferative cell cycle. A wealth of experimental data suggests that quiescence is a vital feature of hematopoietic SCs. 72 Interestingly, the observation that patients may experience recurrence after long periods of disease free-survival has also engendered a longstanding appreciation of quiescence in clinical oncology. 73 Finally, quiescence is considered to be mechanism of resistance to some chemotherapeutics. 74 As alluded to earlier, hematologists speculated as early as the 1960s that fractions of slowly cycling leukemia cells may survive anti-proliferative therapies and contribute to progression. 4 More recently, there has been renewed interest in quiescence as a potential mechanism of chemotherapy resistance in CSCs, particularly in the hematological context. 75 In CML, an early study reported that patient-derived cells exposed to imatinib resulted in the enrichment of a quiescent CD34 þ population, 17 and similar results have since been reported with the second-generation TKIs dasatinib 76 and nilotinib. 77 Moreover, cell cycle induction of quiescent patient derived CD34 þ CML cells with granulocyte colony stimulating factor (G-CSF) improved the efficacy of imatinib in vitro. 78 Interestingly, interferons also provoke cell cycle induction in both normal hematopoietic 79 and CML 80 SCs, suggesting a possible role for these molecules in sensitizing quiescent CSCs to chemotherapy. Finally, CSCs were predominantly quiescent in a mouse model of CML, and this property was regulated by the ubiquitin ligase Fbxw7. 81 Notably, genetic deletion of Fbxw7 increased the Figure 2 . Mechanisms of CSC survival to chemotherapy. The scheme illustrates how combination of standard therapy (green) with the anti-CSC therapy targeting specific pathways (purple) aims to more efficiently eliminate both tumor cell compartments. Each category reflects specific CSC properties that have been exploited to selectively target this population and generate combination strategies with standard chemotherapy.
sensitivity of CSCs to imatinib and improved the survival of CMLbearing mice.
In AML, the contribution of CSC quiescence to chemotherapy resistance has been studied in an elegant xenograft model of human disease. 82 In addition to exhibiting cytarabine resistance, 14 AML SCs were more frequently in G0 than their non-CSC counterparts. Exposure to G-CSF caused AML SCs to acquire a proliferative phenotype, and this transition increased their sensitivity to cytarabine. Moreover, combination therapy with G-CSF and cytarabine significantly reduced disease initiation in secondary recipients, suggesting that cell cycle induction sensitizes chemotherapy-resistant AML SCs to cytarabine. Collectively, these studies suggest that a subset of CML and AML SCs reside in a quiescent state, and that cell cycle induction may sensitize these populations to chemotherapy.
Interestingly, the use of hematopoietic growth factors to sensitize leukemic cells to induction chemotherapy has been evaluated in several clinical trials. Early studies 83, 84 using granulocyte macrophage colony-stimulating factor (GM-CSF) failed to report improved survival. However, more recently two randomized phase III trials using G-CSF and more detailed patient selection and treatment regimen criteria reported positive results. 85, 86 While these results merit continued investigation, they provide proof of principle that cell cycle induction may improve the efficacy of standard chemotherapy in cancer patients.
Epigenetics
Epigenetic mechanisms regulate gene expression in the absence of alterations in DNA sequences. These mechanisms include DNA methylation, histone modification and RNA-mediated targeting, among others, and they regulate many biological processes that are fundamental to cancer. 87 Moreover, epigenetic mechanisms are expected to be fundamental regulators of the CSC state, because CSCs are assumed to be genetically identical to their differentiated progeny. 88 Indeed, a growing body of evidence suggests that a number of epigenetic mechanisms regulate the biological properties of CSCs. For example, considerable progress has been made elucidating the role of microRNAs. An early study reported that Let-7 inhibits breast CSC self-renewal and lack of differentiation by silencing HRAS and HMGA2, respectively. 25 Moreover, members of the miR-200 family also regulate breast CSCs though inhibition of BMI1 89 and the polycomb repressor complex. 90 In prostate cancer, miR34a regulates CSCs through the repression of CD44. 91, 92 In addition, several other epigenetic mechanisms are thought to regulate CSCs. For example, transient inhibition of DNA methylation suppressed CSC properties in an array of hematological and solid malignancies, 93 and the chromatinbinding protein Brd4 maintained the CSC pool in AML. 94 Interestingly, the study of histone deacetylases (HDACs) has also revealed that epigenetic mechanisms may regulate chemotherapy resistance in hematological CSCs. HDACs are chromatin remodeling enzymes that have garnered considerable attention as therapeutic targets in cancer. 95 In an initial study Zhang et al.
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reported that HDAC inhibition suppressed residual CML SCs following imatinib therapy in vivo. Notably, combined exposure to imatinib and a pan-HDAC inhibitor profoundly suppressed the residual bone marrow CSC burden associated with imatinib therapy. In a later study, the same group demonstrated that selective sirtuin HDAC inhibition suppressed CML SC engraftment and growth in vivo in a p53-dependent mechanism. 22 Importantly, both combination strategies improved survival of CML-bearing mice, establishing HDACs as targets to improve the efficacy of TKI therapy in CML.
Collectively, these studies suggest that epigenetic mechanisms are important regulators of CSC biology, and that HDAC inhibition in particular may improve the efficacy of chemotherapy.
Apoptosis/survival pathways Alterations in apoptosis and survival pathways are a hallmark of carcinogenesis. 2 Moreover, a wealth of experimental data indicate that deregulation of apoptosis and survival signaling is also a critical determinant of chemotherapeutic efficacy in established malignancies. 96, 97 In this context, a growing body of evidence suggests that CSCs exploit several mechanisms to deregulate these signaling pathways and promote chemotherapy resistance.
The mitochondrial Bcl2 family proteins are among the bestcharacterized regulators of apoptosis. 98 Interestingly, the antiapoptotic protein Bcl2 protects hematopoietic SCs from apoptotic insults 99 and increases their repopulation potential. 100 Moreover, in an in vivo model of blast crisis CML, bone marrow-derived CSCs exhibited higher expression of Bcl2 protein than their non-CSC counterparts. 23 Notably, this observation stimulated a combination strategy in which inhibition of Bcl2 sensitized chemotherapy-resistant CML SCs to the TKI dasatinib. Bcl2 overexpression also conferred chemotherapy resistance in prostate CSCs, and concurrent inhibition of PI3K/Akt signaling sensitized them to docetaxel. 47 In another study, expression of a highly active pro-apoptotic BIK mutant reduced the frequency of breast CSCs in cell lines and primary patient samples. 101 Moreover, breast tumor-targeted gene therapy with BIK improved the efficacy of the chemotherapeutic agents lapatinib and paclitaxel.
In addition to the deregulation of mitochondrial proteins, secreted cytokines may also constitute a source of pro-survival signaling in cancer. 102 Indeed, treatment of freshly isolated CD133 þ colorectal CSCs with an IL-4 neutralizing antibody sensitized them to 5-fluorouracil and oxaliplatin. 39 Likewise, treatment of colorectal cancer xenografts with an IL-4 receptor antagonist reduced the fraction of CD133 þ cells and improved the efficacy of oxaliplatin. Further, in vitro models of trastuzumab resistance in breast cancer revealed that trastuzumab-resistant CSCs require an IL-6 autocrine signal. 35 Importantly, a combination strategy with an IL-6 receptor antibody potently suppressed acquired trastuzumab resistance in vivo. In addition, a stringent gene signature generated from a large panel of cancer cell lines revealed that the IL-8 receptor CXCR1 is highly expressed by breast CSCs. 103 Interestingly, chemotherapy may increase the CSC pool by stimulating the release of IL-8, whereas a CXCR1 small molecule inhibitor strongly depleted the residual breast CSC population following docetaxel in vivo. 104 Thus, targeting pro-survival cytokine signaling may deplete chemotherapyresistant CSCs.
Moreover, death receptor 5 (DR5) is a pro-apoptotic member of the tumor necrosis factor receptor family and tigatuzumab is a humanized monoclonal antibody that functions as a DR5 agonist. 105 In a series of patient-derived cancer xenografts, pancreatic CSCs exhibited increased DR5 expression and tigatuzumab improved the efficacy of the standard chemotherapeutic gemcitabine.
Finally, developmental signaling pathways are known to promote CSC survival. 5, 8 For example, in CML TGFb-Akt signaling regulated the nuclear localization of FOXO3a, which in turn suppressed apoptosis and imatinib cytotoxicity in CSCs. 106 Indeed, inhibition of the TGFb type I receptor in combination with TKI therapy reduced CSC frequency, disease progression and mortality in a mouse model of CML. Moreover, Hoey et al. 30 reported that the Notch pathway modulates the expression of apoptotic genes in patient-derived colorectal CSCs. Importantly, Notch pathway inhibition potently suppressed relapse after DNA-damaging therapy in vivo. Further, in prostate CSCs Bcl2 expression was regulated by Hh signaling, and Notch2 conferred an additional survival signal through Akt. 47 Combined inhibition of both pathways selectively depleted CSCs and potently suppressed acquired docetaxel resistance in vivo. Thus in addition to selfrenewal, developmental signaling pathways may contribute to chemotherapy resistance by regulating survival signaling in CSCs.
In summary, a growing number of studies indicate that CSCs exhibit chemotherapy resistance through deregulated apoptosis and survival signaling. This deregulation may result from alternations in mitochondrial proteins, cytokine signaling and developmental pathways, among others, and in many cases may constitute a therapeutic opportunity to improve the efficacy of chemotherapy.
Metabolism
The uncontrolled proliferation sustained by many cancers implies a state of deregulated metabolic activity in these diseases. Indeed, in recent years, deregulated metabolism has begun to emerge as a widespread hallmark of cancer. 2, 107 For example, altered glucose metabolism has been appreciated for almost a century and forms the basis for commonly employed imaging modalities in clinical oncology. 108 In addition, numerous other metabolic pathways are now understood to be commonly deregulated in cancer. [109] [110] [111] [112] Recent studies also suggest that CSCs in particular exhibit distinct metabolic features. 113, 114 For example, basal-like breast CSCs exhibited distinct glucose 115 and mevalonate 116 metabolism, and increased glycine decarboxylase expression conferred potent metabolic advantages in lung CSCs. 117 Notably, a series of studies has demonstrated that the metabolic drug metformin exhibits anti-CSC activity and improves the efficacy of chemotherapy. In an initial study, metformin reduced the CSC fraction in four genetically distinct breast cancer cell lines and potently suppressed relapse after doxorubicin therapy in vivo. 118 Further studies extended these results to patient-derived breast cancer cells and revealed that metformin could also improve the efficacy of paclitaxel and carboplatin in vivo. 119 Interestingly, the anti-CSC activity of metformin in breast cancer is specifically attributable to the inhibition of an inflammatory transformation signature. 120, 121 Finally, metformin may also target chemotherapy-resistant CSCs in several other tumor types. [122] [123] [124] Collectively, these recent studies suggest that CSCs exhibit distinct metabolic features and that metabolic drugs like metformin may improve the efficacy of chemotherapy.
Microenvironment
Many adult SCs reside in a supportive microenvironment or niche that consists of mesenchymal, vascular and inflammatory cells, among others, as well as diffusible and cell surface signaling molecules and extracellular matrix components. 125 Moreover, it is now widely appreciated that the microenvironment is a hallmark that regulates virtually every feature of cancer biology. 2 A growing number of studies suggests that CSCs in particular are regulated by the microenvironment, 126, 127 and in some cases this association may constitute an opportunity to improve the efficacy of chemotherapy.
For example, the C-X-C chemokine receptor type 4 (CXCR4) maintains the adult hematopoietic SC pool in the bone marrow niche. 128 Interestingly, TKI exposure induced CXCR4 expression in primary CD34
þ CD38 À CML cells, 129 and blocking the CXCR4 receptor mobilized cells from the bone marrow microenvironment as well as improved the efficacy of nilotinib in vivo. 130 Moreover, it has also been reported that a perivascular niche regulates the tumor-initiating capacity of GBM CSCs, 131 and that tumor-associated vasculature promotes the resistance of GBM CSCs to the DNA-damaging agent temozolomide. 132 Targeting the vascular niche may therefore comprise a strategy to target chemotherapy-resistant CSCs in GBM.
In addition, the microenvironment may regulate chemotherapy resistance in CSCs through mechanisms reviewed in previous sections. For example, as alluded to earlier, Wnt/b-catenin and TGFb family signaling regulate the self-renewal of CML 59, 60 and pancreatic 62 CSCs, respectively, and inhibiting these pathways improved the efficacy of chemotherapy. Interestingly, recent reports suggest that both pathways may be activated by stromal elements in the tumor microenvironment. Indeed, mesenchymal SCs promoted Wnt/b-catenin signaling in CML co-cultures, 133 and patient-derived stellate cells were a source of functional Nodal ligands in pancreatic cancer. 134 Therefore, the microenvironment may contribute to progression in these malignancies by promoting the self-renewal of chemotherapy-resistant CSCs. In addition, as alluded to earlier, Notch signaling promoted chemotherapy resistance in colorectal CSCs through the regulation of anti-apoptotic genes. 30 Interestingly, colorectal CSCs also reside in a perivascular niche, and endothelial cells promoted chemotherapy resistance as a source of a soluble Notch ligand. 135 Finally, the perivascular niche may also secrete soluble ligands that promote quiescence, another known mechanism of chemotherapy resistance in CSCs. 136 Collectively, these data suggest that the microenvironment promotes the chemotherapy resistance of CSCs through several mechanisms; consequently, targeting components of the microenvironment may constitute a promising strategy to improve the efficacy of chemotherapy.
Other CSC mechanisms of resistance to chemotherapy Several CSC mechanisms of resistance to chemotherapy have been described that may not be readily classified into the categories reviewed in the previous sections. For example, the observation that epithelial-mesenchymal transition confers CSC properties was recently exploited to screen for specific anti-CSC agents. 137 The DNA-damaging agent salinomycin reduced the sphere-forming and tumor-initiating capacity of breast cancer cells, as well as the expression of a prognostic breast CSC gene set. Furthermore, combined treatment of MCF7 spheres with salinomycin improved the efficacy of trastuzumab. 138 In addition, the HGF/c-Met signaling pathway has been studied in the CSC context. For example, HGF promoted CSC properties in colorectal cancer, 139 whereas the c-Met inhibitor XL184 reduced the fraction of CD44 þ /c-Met þ CSCs in pancreatic cancer. 42 Notably, c-Met inhibition also improved the efficacy of gemcitabine in patient-derived pancreatic cancer xenografts. Finally, ABC transporters have long been studied as agents of multidrug resistance in cancer. 140 Interestingly, the expression of ABC drug transporters by both adult SCs and CSCs has sometimes enabled the enrichment of these fractions through the side population assay. 141 Accordingly, targeting ABC transporters in cancer generally and CSCs in particular has garnered considerable interest as a strategy to suppress chemotherapy resistance. However, to date, the outcomes of studies with three generations of inhibitors have unfortunately been negative, possibly because of pharmacokinetic interactions or the presence of additional transporters. 142 Thus, targeting CSCs through their overexpression of ABC transporters remains an unresolved question that merits further investigation.
EVOLVING COMPLEXITY OF THE CSC MODEL AND IMPLICATIONS FOR CHEMOTHERAPY RESISTANCE
Acquired resistance to chemotherapy has significantly curtailed cancer survival for more than half a century. As detailed above, the CSC model comprises a fruitful paradigm that has in many instances elucidated biological mechanisms underlying acquired resistance as well as stimulated combination strategies that may suppress this consequential event in the future. Nonetheless, a number of important considerations may limit the applicability of the CSC model to acquired chemotherapy resistance. These considerations are discussed below.
Some cancers may not exhibit a cellular hierarchy. For example, the frequency of tumor-initiating cells in human melanoma varied dramatically between the NOD/SCID and NOD/SCID Il2rg À / À (NSG) recipient strains, 143, 144 and a large number of cell surface markers failed to meet the CSC criteria in NSG mice. 145 These studies suggested that immunological barriers in the NOD/SCID strain may skew the validity of xenotransplantation data and erroneously support the CSC model. In contrast, a more recent melanoma study reported that ALDH activity may enrich for tumor-initiating cells using the NSG strain. 146 Therefore, at present it is unclear whether human melanoma exhibits a cellular hierarchy. However, it is important to note that considerably less variability has been observed between the NOD/SCID and NSG strains with human AML, 11 colon, 139 lung, 147 pancreatic 147 and prostate 47 CSCs, among others. Moreover, although cell surface and enzymatic markers have been widely implemented in CSC studies, their utility is limited by several considerations. For example, CSC markers may typically be co-expressed by non-CSC populations, they may vary considerably between patients with the same disease and they may exhibit plasticity throughout therapeutic and experimental manipulations, among others. 5, 7, 8 In addition, it is important to note that serial propagation in vivo and not cell surface or enzymatic markers is the defining characteristic of CSCs. [5] [6] [7] [8] Indeed, changes in CSC markers are only suggestive of changes in CSCs, and do not constitute formal proof. Therefore, caution is warranted in the interpretation of CSC studies that implement markers, particularly in the context of experimental models in which the CSC model has not been rigorously validated. Ideally, single-cell lineage-tracing experiments should be implemented in order to circumvent these limitations, although the level of commitment in terms of material and personnel required for such studies may not be widely practicable. 148 As a minimum, in vivo serial transplantation should be implemented in order to validate substantial changes in CSC frequencies. Indeed, many, though not all, of the studies reviewed here addressed changes in the CSC population by this more rigorous criterion. 14, [21] [22] [23] 30, 34, 35, [45] [46] [47] 59, 60, 65, 82, 104 Furthermore, a growing number of studies suggest that many CSC properties exhibit a considerable degree of phenotypic as well as functional plasticity, insofar as populations lacking CSC markers and tumor-initiating capacity may give rise to populations that express CSC markers and exhibit high tumor-initiating capacity. 5, 7, 8 For example, ectopic expression of transcription factors that promote epithelial-mesenchymal transition may facilitate this conversion. 149, 150 Interestingly, epithelialmesenchymal transition may also be associated with enhanced resistance to chemotherapy. 151 In addition, a number of soluble ligands that may be present in the tumor microenvironment also facilitate the conversion of non-CSCs to CSCs, including HGF, 139 IL-6, 122 TGFb 149, 150, 152 and Jagged-1, 135 among others. Notably, recent and highly complementary studies indicate that chemotherapy resistance is also subject to considerable plasticity, [153] [154] [155] suggesting that cancer cells may reversibly transition among epigenetically defined tumorigenic as well as chemotherapyresistant states. Importantly, however, this emerging complexity in the CSC field does not negate the therapeutic strategies reviewed here that highlight the significance of combining chemotherapy with anti-CSC agents to suppress acquired resistance. To the contrary, this enhanced appreciation of CSC plasticity emphasizes the importance of a combined therapeutic approach.
In addition, it is important to note that a limited number of studies have demonstrated that some standard chemotherapeutics may be toxic to CSCs. For example, sublethal concentrations of temozolomide reduced the tumor-initiating capacity of GBM CSC lines. 156 However, other studies using primary cell lines, 51 in vivo models 54 and clinical samples 52 suggested that CSCs are resistant to temozolomide, indicating that the contribution of GBM CSCs to chemotherapy resistance may vary between experimental models. Moreover, reports that standard chemotherapeutics are toxic to CSCs in some contexts are not inconsistent with classic tenants of clinical oncology. Chemotherapy is known to be curative in a subset of leukemia patients, 9 as well as when administered as adjuvant therapy to breast 157 and colon 158 cancer patients, among others. These clinical observations suggest that CSCs in some patients are sensitive to chemotherapy. Indeed, investigating the mechanisms by which CSCs are sensitive or resistant to chemotherapy may improve the prospect of individualized combination strategies.
Finally, a potential conceptual pitfall associated with applying the CSC model to acquired chemotherapy resistance should also be noted. If CSCs are the sole cellular fraction endowed with chemotherapy resistance in the acquired setting, then tumors that are repopulated with non-CSC progeny would again be expected to respond to chemotherapy. However, this sequence is rarely observed in clinical oncology. Therefore, if a minority population of CSCs indeed contributes to progression after chemotherapy, then it would be expected that either (1) relapsed tumors are constituted entirely by a vastly expanded CSC fraction or (2) CSCs give rise to chemotherapy-resistant non-CSC progeny. Several studies now suggest that the former is unlikely because relapsed tumors typically contain only a minority population of cells endowed with the phenotypic and functional properties of CSCs. 25, 26, 47, 66 Therefore, it would be expected that during the process of progression, CSCs confer their non-CSC progeny with chemotherapy-resistant properties. Although this is currently a poorly understood area, elucidating the mechanisms by which CSCs give rise to chemotherapy-resistant non-CSC progeny may be of considerable clinical interest in the future.
PERSPECTIVES FOR CLINICAL ONCOLOGY
A significant measure of the applicability of CSC concepts to acquired chemotherapy resistance will emerge from the clinical setting. Indeed, many of the anti-CSC agents that were identified in studies reviewed here are currently in clinical development (Table 1) , and some are even being evaluated in combination with standard chemotherapy. However, the application of anti-CSC agents to suppress acquired resistance will necessitate several careful considerations, particularly in the context of early clinical development (Figure 3) .
Generally speaking, the efficacy of anticancer agents is determined in large phase III clinical trials by virtue of their impact on overall survival. In this context, anti-CSC agents that suppress the acquisition of resistance during standard chemotherapy would be expected to diminish disease progression and consequently improve overall survival. However, because this standard is not achievable in early clinical development, phase II trials in particular require surrogate endpoints, for example biochemical and radiographical measures of tumor burden. However, targeting typically small subpopulations of CSCs in combination with chemotherapy would not be expected to produce significant measurable changes in tumor burden. This observation raises the unfortunate prospect that combination strategies that aim to suppress acquired resistance to standard chemotherapy may be abandoned in the setting of early clinical development despite possible improvements in overall survival. Therefore, the addition of anti-CSC agents to standard chemotherapeutic regimens will require the introduction of new surrogate endpoints.
Fortunately, renewed interest in the CSC model in recent years has resulted in the identification of several potential surrogate endpoints. Ideally, these 'CSC endpoints' would be monitored serially throughout anti-CSC therapy.
First, CSC populations have frequently been enriched using markers that are detectable by flow cytometry. While the utility of these markers has been mitigated by the discovery of marker heterogeneity and plasticity, the concomitant analysis of several markers may be informative. In addition, a growing number of studies have identified CSC transcriptome signatures. In breast cancer 159 and AML, 11 these signatures exhibited significant prognostic value. Moreover, a recent study reported that docetaxel chemotherapy enriched for a CSC signature in breast cancer patients. 29 Therefore, the efficacy of anti-CSC agents may be evaluated though transcriptome profiling. Interestingly, recent technological advances may facilitate this assessment with exceedingly small numbers of cells. 160 Finally, as alluded to earlier, rigorous validation of the CSC model entails in vivo transplantation studies. Therefore, the efficacy of anti-CSC agents would be best evaluated by estimating their impact on the frequency of tumor-initiating cells. Although this method is more costly and complex, the results are more definitive. Ultimately, however, estimating the number of sphere-forming cells may prove more practicable, though some degree of caution is necessary in the interpretation of results using this assay. 5, 6, 8 Assessing the ability of anti-CSC agents to suppress acquired resistance to standard chemotherapy in early clinical development may also demand several important inclusion criteria. For example, the evaluation of 'CSC endpoints' implies that serially obtained clinical materials will be necessary. As a minimum, this would include baseline and post-combination therapy samples. Therefore, patients who are unfit or unwilling to provide serial biopsies for the evaluation of surrogate endpoints may hinder the assessment of anti-CSC efficacy. Interestingly, however, this challenging limitation may eventually be circumvented by the measurement of circulating tumor cells in blood samples. Indeed, a growing body of evidence suggests that circulating tumor cells may contain measurable CSC marker-expressing cells. [161] [162] [163] [164] Moreover, the definition of acquired resistance implies that combination therapies that aim to suppress this event must be evaluated in chemotherapy-sensitive patients. Indeed, most of the preclinical studies reviewed here have assessed the efficacy of combination therapies in the context of chemotherapy-sensitive disease. Therefore, it is unclear whether combination therapies that include anti-CSC agents would benefit patients who exhibit primary or acquired resistance prior to enrollment in a clinical trial.
In addition, toxicity is a paramount consideration in the clinical development of anticancer agents. This consideration may be particularly significant in the context of anti-CSC agents, because many of the CSC mechanisms of resistance to chemotherapy reviewed here are known to be active in adult SCs in addition to other cellular counterparts. This observation raises the question of whether anti-CSC agents may be especially susceptible to doselimiting toxicities.
While it is almost impossible to accurately predict such toxicities before human trials, in vivo models may provide opportunities, particularly in the adult SC context. For example, several studies reviewed here examined the impact of anti-CML SC agents on normal hematopoietic SCs. In one study, the combination of imatinib and the HDAC inhibitor LBH589 only moderately affected hematopoiesis in wild-type mice. 21 In another study, the combination of dasatinib with the Bcl2 family inhibitor sabutoclax failed to significantly impact the engraftment of normal hematopoietic SCs into secondary recipients. 23 Finally, detailed analyses revealed that genetic deletion of the ubiquitin ligase Fbxw7 more significantly inhibited CML SCs than normal hematopoietic SCs. 81 Thus, in vivo models may provide an opportunity to investigate the potential toxicities associated with anti-CSC agents.
In summary, the implementation of anti-CSC agents to suppress acquired resistance to standard chemotherapy will necessitate several careful considerations, particularly in early clinical development. These considerations include the application of specialized surrogate endpoints, the selection of patients most likely to benefit from combination strategies that curtail acquired resistance and the anticipation of toxicities associated with anti-CSC agents. Importantly, an innovative study recently investigated the applicability of these considerations to the clinical setting. Schott et al. conducted a phase II trial in which an anti-CSC Notch inhibitor was combined with standard docetaxel chemotherapy in breast cancer. 66 'CSC endpoints', including a combination of markers and functional assays, were serially measured, patients with previous progression on taxane therapy were not included and addition of an anti-CSC agent to standard chemotherapy did not appear to confer severe toxicities. This study provides a proof of principle that the considerations discussed here may be implemented in the setting of early clinical anti-CSC therapy development.
Finally, it is important to note that while the studies and considerations reviewed here relate primarily to the suppression of acquired resistance in disseminated cancers that exhibit a measurable tumor burden, anti-CSC agents may also improve the efficacy of chemotherapy in the adjuvant setting in which tumor burden is difficult to measure. 33 This notion is substantiated by the observation that the addition of trastuzumab, an agent with known anti-CSC properties, 32, 34 to standard chemotherapy in the adjuvant setting has resulted in improvements in overall survival for breast cancer patients with HER2-overexpressing disease. 31 Therefore, the capacity of anti-CSC agents to cooperate with chemotherapy in the adjuvant setting may also be of particular interest in the future.
CONCLUSION
Chemotherapy is a critical component in the therapeutic landscape for nearly every category of cancer. Unfortunately, although chemotherapy frequently succeeds in reducing tumor burden, the efficacy of many agents is limited by acquired resistance. As reviewed here, the last several years have ushered a substantial and growing body of evidence that CSCs contribute to this phenomenon. Importantly, the detailed characterization of CSCs has resulted in new combination strategies that improve the efficacy of chemotherapy in preclinical models. These promising developments may open a new chapter in the chemotherapy age in which acquired resistance will exert a reduced impact on cancer survival.
